ARCHIVES

Addition of Cobimetinib Boosts PFS in BRAF Mutation-Positive Patients in Phase III Trial

This article is from The Cancer Letter archive.

Vol. 37 No. 7 | July 25, 2014

Download PDF Visit The Full Archive

Related Articles

Cancer Center Directors to Develop Blueprint for Progress That’s “Honest,” M.D. Anderson’s John Mendelsohn Says.

November 22, 2006

NCI Could Fund Some Challenge Grants That Miss NIH Funding, Director Says

June 26, 2009

FDA Warns of Lymphoma Risk Associated With Breast Implants

January 28, 2011

In Brief: Senate committee Oks Another Cigarette Tax Hike; NCI Seeking Cancer Control Science Head

August 1, 1986

NCI Plans $61 Million For Six-Year Program In Biomarker Research For Early Detection

December 4, 1998

NCI plans 11-16 percent budget cuts in new grants to maintain R01 payline at 20th percentile.

November 28, 2003